title: FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations.
abstract: In Japan, the use of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) for some malignant tumors came to be covered by the National Health Insurance in 2002. In 2010, the health insurance coverage was expanded to all types of malignant tumors. However, since PET examination requires a large amount of capital investment, facilities at which PET is available are still limited. On the other hand, PET equipment has rapidly been introduced in large hospitals and in the diagnostic imaging centers of major cities during the past few years. Although numerous middle-sized and small hospitals cannot afford to perform PET, physicians can refer their patients to facilities where PET is available. Therefore, it is essential for general physicians to gain accurate knowledge on PET, including the appropriate indications for PET, in order to select patients for referral to PET facilities. PET is not always a useful tool, especially for lesions of the pancreas and hepatobiliary system, which is the main topic of this review. The indications of PET for lesions in these organs vary depending on the purpose of the examination. In this article, we review the indications for PET (or PET/computed tomography [CT]) using FDG of the liver, biliary tract, and pancreas.
authors: Koji Murakami, Division of Nuclear Medicine, Department of Radiology , School of Medicine, Keio University, 35 Shinanomachi, Shinjyuku-ku, 160-8582 Tokyo, Japan.
authors: Koji
authors: K
authors: Murakami
references: J Gastroenterol. 2004 Oct;39(10):961-8
references: 15549449
references: Ann Nucl Med. 2000 Apr;14(2):121-6
references: 10830530
references: Am J Gastroenterol. 1999 Nov;94(11):3314-9
references: 10566736
references: Clin Nucl Med. 2007 Apr;32(4):282-5
references: 17413574
references: Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1285-9
references: 16802155
references: J Hepatol. 2006 Jul;45(1):43-50
references: 16690156
references: World J Surg. 2006 Sep;30(9):1736-41
references: 16850145
references: Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1047-54
references: 12173019
references: J Clin Oncol. 2002 Jan 15;20(2):388-95
references: 11786565
references: J Nucl Med. 2003 Feb;44(2):213-21
references: 12571212
references: Pancreatology. 2005;5(2-3):266-72
references: 15855825
references: Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1467-72
references: 14579085
references: J Surg Oncol. 2003 Oct;84(2):74-81
references: 14502780
references: J Nucl Med. 1995 Oct;36(10):1811-7
references: 7562048
references: Anticancer Res. 2005 Nov-Dec;25(6C):4591-4
references: 16334147
references: Mol Imaging Biol. 2010 Apr;12(2):139-44
references: 19626378
references: J Gastrointest Surg. 2004 Jan;8(1):90-7
references: 14746840
references: Br J Surg. 1999 Feb;86(2):194-9
references: 10100786
references: Hepatology. 1998 Sep;28(3):700-6
references: 9731562